GH/IGF-I axis in Prader-Willi syndrome: Evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli

Journal of Endocrinological Investigation

Volumn 23, Issue 2, 2000, Pages 84-89

  Corrias, A ^a,g   Bellone, J ^a   Beccaria, L ^h   Bosio, L ^h   Trifiro G ^b   Livieri, C ^h   Ragusa, L ^c   Salvatoni, A ^d   Andreo, M ^a   Ciampalini, P ^f   Tonini, G ^e   Crino A ^f  

^a REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c OASI RESEARCH INSTITUTE IRCCS   (Italy)

^d OSPEDALE DI CIRCOLO   (Italy)

^e INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^f BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^g Division of Pediatric Endocrinology   (Italy)

^h NONE

Author keywords

Arginine; Clonidine; GH; GHRH; IGF I; Obesity; Prader Willi syndrome; Pryidostigmine

Indexed keywords

ARGININE; CLONIDINE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; PYRIDOSTIGMINE; SERMORELIN; SOMATOMEDIN C;

ARTICLE; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; FEMALE; GROWTH HORMONE DEFICIENCY; HORMONE RESPONSE; HUMAN; MALE; OBESITY; PRADER WILLI SYNDROME; STIMULUS RESPONSE; TREATMENT OUTCOME;

EID: 0034030592     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03343684     Document Type: Article

References (35)

1. Ledbetter D., Riccardi V., Airhart S., Strobel R., Keenen S., Crawford J. Deletion of cromosome 15 as a cause of the Prader Willi Syndrome. N. Engl. J. Med. 1981, 11: 304-325.
2. Carrozzo R., Rossi E., Christian S., Kittickamron K., Livieri C., Corrias A., Pucci L., Fois A., Simi P., Bosio L., Beccaria L., Zuffardi O., Ledbetter D. Inter and intrachromosomal rearrangements qre bth involved in the origin of 15 q11-q13 deletion. Am. J. Hum. Genet. 1997, 61: 228-232.
3. Nicholls R., Knoll J., Butker M., Karam S., Lalande M. Genetic imprinting suggested by maternal heterodisomy in nondeletion Prader Willi syndrome. Nature (London) 1989, 342: 281-285.
4. Holm V.C., Cassidy S.B., Butler M.G., Hanchett J.M., Greenswag L.R., Witman B.Y., Greemberg F. Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics 1993, 91: 398-402.
5. Donaldson M., Chu C., Cooke A., Wilson A., Greene S., Stephenson J. The Prader Willi syndrome. Arch. Dis. Child. 1994, 70: 58-63.
6. Hanson J. A view of etiology and pathogenesis of Prader - Willi syndrome. In: Holm V.A., Sulzbacher S.J., Pipe P.L. (Eds.), The Prader-Willi syndrome. University Park Press, Baltimore, 1981, p. 45.
7. Swaab D., Purba J. S., Hofman M.A. Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases. J. Clin. Endocrinol. Metab. 1995, 80: 573-579.
8. Costeff H., Holm V.A., Ruvalcaba R., Shaver J. Growth hormone secretion in Prader-Willi syndrome. Acta Paediatr. Scand. 1990, 79: 1059-1062.
9. Cappa M., Grossi A., Borrelli P., Ghigo E., Bellone J., Benedetti S., Carta D., Loche S. Growth homone (GH) response to combined Pyridostigmine and GH-releasing hormone administration in patients with Prader - Labhard - Willi Syndrome. Horm. Res. 1993, 39: 51-55.
10. Angulo M., Castro -Magana M., Mazur B., Canas J., Vitollo P., Sarrantonio M. Growth hormone secretion and effects of growth hormone therapy on growth velocity and weight gain in children with Prader Willi Syndrome. J. Paed. Endocrinol. Metab. 1996, 9: 393-400.
11. Beccaria L., Bosio L., Sanzari A., Aimaretti G., Ghigo E., Chiumello G. GH secretion in Prader-Labhard - Willi Syndrome: somatotrope responsiveness to GHRH is enhanced by arginine but not by pyridostigmine. J. Paed. Endocrinol. Metab. 1996, 9: 577-583.
12. Grugni G., Guzzaloni G., Moro D., Bettio D., De Medici C., Morabito F. Reduced growth hormone (GH) responsiveness to combined GH-releasing hormone and pyridostigmine administration in the Prader Willi syndrome. Clin. Endocrinol. 1998, 48: 769-775.
13. Ranke M.B., Haber P. Growth hormone stimulation tests. In: Ranke M.B. (Eds.), Functional endocrinologic diagnostic in children and adolescents. I.&J., Verlag Mannheim, 1992, p. 61.
14. Ghigo E., Bellone J., Aimaretti G., Bellone S., Loche S., Cappa M., Bartolotta E., Dammacco F., Camanni F. Reliability of provocative tests to assess growth hormone secretory status. Study in 472 normally growing children. J. Clin. Endocrinol. Metab. 1996, 81: 3323-3327.
15. Cole T.J. A method for assessing age standardised weight for height in children seen cross sectionally. Ann. Hum. Biol. 1979, 7: 457-473.
16. Iranmanesh A., Lizarralde G., Veldhuis J.D. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory burts and the half-life of endogenous GH in healthy man. J. Clin. Endocrinol. Metab. 1991, 73: 1081-1088.
17. Veldhuis J.D., Iranmanesh A., Ho K.K.Y., Waters M.J., Johmson M.L., Lizarralde G. Dual defect in pulsatile growth hormone secretion and clearance subserve the hyposomatotropinism of obesity in man. J. Clin. Endocrinol. Metab. 1991, 72: 51-59.
18. Topper E., Gil-Ad I., Bauman B., Josefaberg Z., Laron Z. Plasma growth hormone response to oral clonidine as compared to insulin hypoglicemia in obese children and adolescents. Horm. Metab. Res. 1984, 1: 127-130.
19. Loche S., Balzano S., Bozzola M., Moretta A., Pintus S., Faedda A., Muntoni A., Carta D., Pintor C. Secretion of growth hormone releasing hormone in obese children. J. Endocrinol. Invest. 1992, 15: 453-457.
20. Cordido F., Casanueva F.F., Dieguez C. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects. J. Clin. Endocrinol. Metab. 1989, 68: 290-293.
21. Rasmussen M.H., Hvidberg A., Juul A., Main K.M., Gotfredsen A., Skakkebaek M., Hilsted J. Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I in obese subjects. J. Endocrinol. Metab. 1995, 80: 1407-1415.
22. Tannenbaum G.S., Lapointe M., Gurd W., Finkelstein J.A. Mechanism of impaired growth hormone secretion in genetically obese zucher rats: roles of growth hormone-releasing factor and somatostatin. Endocrinology 1990, 127: 3087-3091.
23. Ghigo E., Mazza E., Corrias A., Imperiale E., Goffi S., Arvat E., Bellone J., de Sanctis C., Muller E.E., Camanni F. Effect of cholinergic enhancement by pyridostigmine on growth hormone secretion in obese adults and children. Metabolism 1989, 38: 631-633.
24. Ghigo E., Procopio M., Maccario M., Bellone J., Arvat E., Campana S., Boghen M.F., Camanni F. Repetitive GHRH administration fails to increase to GHRH in obese subjects. Evidence for a somatotrope defect in obesity? Horm. Metab. Res. 1993, 25: 305-308.
25. Maccario M., Procopio M., Grottoli S., Oleandri S.E., Boffano G.M., Taliano, M., Camanni F., Ghigo E. Effects of acipimox, an antilipolytic drug, on the growth hormone (GH) response to GH-releasing hormone alone or combined with arginine in obesity. Metabolism 1996, 45: 1-6.
26. Cordido F., Peino R., Penalva A., Alvarez C.V., Casanueva F.F., Dieguez C. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression. J. Clin. Endocrinol. Metab. 1996, 81: 914-918.
27. Frystyk J., Skjaerbaek E., Mogensen C.E., Orskov H. Free insulin-like growth factor in human obesity. Metabolism 1995, 44 (Suppl. 4): 37-44.
28. Loche S., Cappa M., Borrelli P., Faedda A., Crinò A., Cella S.G., Corda R., Muller E.E., Pintor C. Reduced growth hormone response to growth hormone-releasing hormone in children with simple obesity: evidence for a somatomedin-C mediated inhibition. Clin. Endocrinol. (Oxf.) 1987, 27: 145-150.
29. Rudman D., Kutner M.H., Rogers C.M., Lubin M.F., Fleming G.A., Bain R.P. Impaired growth hormone secretion in adult population: relation to age and adiposity. J. Clin. Invest. 1981, 67: 1361-1369.
30. Ghigo E., Bellone J., Mazza E., Imperiale E., Procopio M., Valente F., Lala R., de Sanctis C., Camanni F. Arginine potentiates the GHRH- but not the pyridostigmine-induced GH secretion in normal short children. Further evidence for a somatostatin suppressing effect of arginine. Clin. Endocrinol. (Oxf.) 1990, 32: 763-767.
31. Ghigo E., Arvat E., Goffi S., Nicolosi M., Arvat E., Procopio M., Bellone J., Valente F., Ghigo M.C., Camanni F. Repetitive GHRH and arginine administration to explore the maximal secretory capacity of somatotrope cells during lifespan. Clin. Exp. Endocrinol. 1991, 10: 191-198.
32. Blum W.F., Albertson-Wiekland K., Rosberg S., Ranke M.B. Serum levels of insulin-like growth factor (IGF-I) and IGF-I binding protein 3 spontaneous growth hormone secretion. J. Clin. Endocrinol. Metab. 1993, 76: 1610-1616.
33. Grosso S., Cioni M., Buoni S., Peruzzi L, Pucci L., Berardi P. Growth hormone secretion in Prader-Willi syndrome. J. Endocrinol. Invest 1998, 21: 418-422.
34. Valetto M.R., Bellone J., Baffoni C., Savio P., Aimaretti G., Gianotti L., Arvat E., Camanni F., Ghigo E. Reproducibility of the growth hormone response to stimulation with growth hormone-releasing plus arginine during lifespan. Eur. J. Endocrinol. 1996, 135: 568-572.
35. Cappa M., Loche S., Salvadori R., Faedda A., Borrelli P., Cella S.G., Pintor C., Muller E.E. The GH response to pyridostigmine plus GHRH is not influenced by pubertal maturation. J. Endocrinol. Invest. 1991, 14: 41-45.